1. Therapeutic Treatment of Resveratrol on Alzheimer’s Disease with CL2006 Sohrab Vatsia

2. Need Figure 1Figure 2 http://uscnews2.usc.edu/Publication_JPGS/HSCWeekly/2003/HSCW2665p1.jpghttp://www.omh.state.ny.us/omhweb/Statewideplan/2005/images/figure4.2.gif

3. Alzheimer’s Disease http://www.nia.nih.gov/NR/rdonlyres/A294D332 -71A2-4866-BDD7- A0DF216DAAA4/0/Alzheimers_Disease_Unraveli ng_the_Mystery.pdf Figure 1 Figure 2 Figure 3 Figure 1 http://www.nia.nih.gov/NR/rdonlyres/A294D332- 71A2-4866-BDD7- A0DF216DAAA4/0/Alzheimers_Disease_Unraveling_th e_Mystery.pdf

4. Resveratrol http://www.resveratrol.org.uk/resveratrol.gif Rogers, Kara, ed. "Alzheimer's Disease." Encyclopedia Britannica. 15th ed. 2002. 306-07.

5. Resveratrol’s Role http://www.chiro.org/nutrition/ABSTRACTS/Resveratrol_in_Prevention_and_Treatment.pdf

6. CL2006 http://wormsrus.50webs.com/Nematodes/C%20elegans.JPG

7. Literature Review Marambaud, 2008 (Marambaud, 2008)

8. Literature Review Vingtdeux, 2005 (O’Neill, 2002)

9. Literature Review Anekonda, 2006 (Rodgers, 2006)

10. Literature Review Duchen, 2004 (Marambaud, 2005)

11. Hypothesis/ Purpose The purpose of the experiment is to analyze the therapeutic and preventative potential of Resveratrol on Alzhemier’s disease. Alternate - with the administration of Resveratrol in the CL 2006 model, amyloid-beta production will slow, and the spread of the amyloid-beta molecules will reduce. Null - There will be no change in amyloid beta production nor paralysis with the addition of Resveratrol.

12. Protocols Preparation of Bacterial Plates (Siernagle, 2009) (Yun, 2007)

13. Protocols Resveratrol Administration (Halliwell, 2004) Concentration <or = to 100 micromolars (Lenker, 2001)

14. Protocols C. elegans synchronization Paralyzed versus Non-Paralyzed (Cheng,2002)

15. Protocols Staining using Congo Red Dye-registers Amyloid Beta Plaques (Zhao, 1999)

16. Do-Ability This project is do-able because we have all the necessary materials in the lab C. elgegans (both CL 2006 and wild-type) are readily available as well as their environments ie; plates, food, living conditions Resveratrol is also readily available, it can be purchased relatively easily Amyloid Stain is readily available Microscope/s are available along with the prism and a Motic camera are also readily available; thus observation is do-able

18. C. Elegans Control CL 2006 ControlC. Elegans adminstered Resveratro l(negative control) CL 2006 Resveratrol (Preventative) Monitor LifespanStain and monitor amyloid levels, as well as monitor lifespan CL 2006 Resveratrol Therapeutic Monitor Life Span, Stain, and obeserve amyloid- beta levels Treat with Resveratrol prior to paralysis. Measure Lifespan, stain,and measure amyloid-beta levels. Treat on the onset of paralysis. Measure lifespan, stain, and measure amyloid- beta levels Record Qualitative and Quantitative Data based upon the observations, and following the protocols, (Lifespan, Amyloid-Beta Levels) CL 2006 Gamma- Secretase Tested in order to make sure that the amyloid-beta is being targeted (2 or 3 trials) Statistical Analysis by Two Way Anova followed by Scheffe Post-Hoc (p<.05)

19. Bibliography Bundschuh, K. "The worm in humans." 11 Nov. 2008. Biotechnology and Life Sciences in Baden-Württemberg. 6 May 2009. Cheng, Louse. “Compound in Red Wine May Fight Alzeimer’s.” WebMD. 4 Nov. 2005. 15 Apr. 2009.http://www.webmd.com/alzheimers/news/20051104/compound-in-red-wine-may- fight-alzheimer>. Duchen, Michael R. "Roles of Mitochondria in Health and Disease." Whereas some of the genes identified in the control of longevity appear to target mitochondria or at least to alter antioxidant defenses of the cell (Duchen, 2004. 2004. Diabetes. 7 May 2009. Halliwell, Barry, and John M.C. Gutteridge. Free Radicals in Biology and Medicine. 3rd ed. New York: Oxford UP, 2004. Lagouge, Marie, Carmen Argmann, Zachary Gerhart-Hines, Hamid Meziane, Carles Lerin, Frederic Daussin, Nadia Messadeq, Jill Milne, Philip Lambert, Peter Elliott, Bernard Geny, Markku Laakso, Pere Puigserver, and Johan Auwerx. "Resveratrol Improves Mitochondrial Function and Protects Against Metabolic Disease by Activating SIRT1 and PGC-1a." Cell (2006). 20 May 2008. Lenker, David P. Professional Guide to Diseases. 8 th ed. New York: Williams & Wilkins., 2005 Marambaud, Phillipe. Wine Compound May Help Cut Risk of Alzheimer’s Disease. 16 Nov. 2005. 24 Apr. 2009.http://www.sciencedaily.com/releases/2008/06/080617165716.htm>. McKenzie, Maureen A. "Insulin Receptor-Like Protein." Patent Storm. 5 Oct. 1992. 18 Apr. 2008. O,Neill, Bill. "In Methuselah’s Mould." Feature 2 (2004): 0014-017. PLoS Biology..http://www.culturagalega.org/imaxes/docs/plos_lonxevidade.pdf>. "Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease ( whether any of the Company's product ca...)." Bio-Medicine - latest biology and medical news/technology. 26 June 2007. 29 Apr. 2009. Rodgers, Anne B. "Alzheimer's Disease: Unraveling the Mystery." Alzheimer's Disease NIH 2005 (2003). Rogers, Kara, ed. "Alzheimer's Disease." Encyclopedia Britannica. 15th ed. 2002. 306-07. Society for Neuroscience. "Grape Seed Extract May Reduce Cognitive Decline Associated With Alzheimer's Disease." ScienceDaily 18 June 2008. 29 April 2009. Vingtdeux, Valérie, Ute Dreses-Werringloer, Haitian Zhao, Peter Davies, and Philippe Marambaud. "Therapeutic potential of resveratrol in Alzheimer's disease." BMC Neuroscience 9 (2008): 1-5.